Korro Bio FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 EPS estimate for Korro Bio from ($8.76) to ($10.49), while maintaining a "Strong-Buy" rating on the stock.
• Several analysts have lowered their price targets for Korro Bio, with HC Wainwright setting a new target of $90.00 and Oppenheimer adjusting it down to $90.00 as well.
• Korro Bio's shares have experienced a recent decline, trading down 1.9% to $19.50, amidst a market cap of approximately $183.11 million.

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Korro Bio in a research report issued to clients and investors on Wednesday, August 13th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the company will post earnings per share of ($10.49) for the year, down from their prior estimate of ($8.76). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. Cantor Fitzgerald also issued estimates for Korro Bio's FY2026 earnings at ($8.88) EPS.

A number of other equities analysts have also weighed in on KRRO. HC Wainwright reduced their price objective on Korro Bio from $100.00 to $90.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. Raymond James Financial dropped their target price on Korro Bio from $153.00 to $147.00 and set a "strong-buy" rating on the stock in a report on Wednesday, August 13th. Oppenheimer decreased their price target on Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Finally, Chardan Capital restated a "buy" rating and issued a $25.00 price objective on shares of Korro Bio in a research report on Wednesday, August 13th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Korro Bio currently has a consensus rating of "Buy" and a consensus price target of $86.83.

Korro Bio Price Performance

NASDAQ:KRRO traded down $0.54 during mid-day trading on Friday, hitting $19.72. The company's stock had a trading volume of 162,738 shares, compared to its average volume of 145,722. Korro Bio has a 1 year low of $10.29 and a 1 year high of $98.00. The stock has a market cap of $185.17 million, a price-to-earnings ratio of -2.02 and a beta of 2.51. The business's fifty day moving average is $14.41 and its two-hundred day moving average is $17.80.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($2.74) earnings per share for the quarter, missing analysts' consensus estimates of ($2.54) by ($0.20). The firm had revenue of $1.46 million for the quarter, compared to analysts' expectations of $0.41 million.

Institutional Trading of Korro Bio

Several institutional investors have recently bought and sold shares of KRRO. Balyasny Asset Management L.P. purchased a new position in shares of Korro Bio during the 4th quarter valued at approximately $220,000. Legal & General Group Plc raised its position in Korro Bio by 664.1% during the fourth quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock worth $165,000 after acquiring an additional 3,759 shares during the period. GAMMA Investing LLC raised its position in Korro Bio by 128,950.0% during the first quarter. GAMMA Investing LLC now owns 10,324 shares of the company's stock worth $180,000 after acquiring an additional 10,316 shares during the period. Deutsche Bank AG lifted its holdings in Korro Bio by 29.4% during the fourth quarter. Deutsche Bank AG now owns 4,110 shares of the company's stock valued at $156,000 after purchasing an additional 935 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Korro Bio by 9.0% in the first quarter. Bank of New York Mellon Corp now owns 16,113 shares of the company's stock valued at $281,000 after purchasing an additional 1,325 shares during the period. 13.18% of the stock is owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).